Taysha Gene Therapies, Inc. TSHA Enterprise value

Enterprise value at other companies

Ionis PharmaceuticalsIONS

$13.02B+91.2%

BiogenBIIB

$38.17B+70.8%

Acadia PharmaceuticalsACAD

$4.02B+13.2%

Ultragenyx PharmaceuticalRARE

$1.83B-51.1%

uniQureQURE

$2.82B+376%

Design Therapeutics, Inc.DSGN

$646.16M+211%

FAQ

What is Taysha Gene Therapies, Inc.'s enterprise value?

Taysha Gene Therapies, Inc. (TSHA) reported enterprise value of $1.08B in Q1 2026.

How has Taysha Gene Therapies, Inc.'s enterprise value changed year-over-year?

Taysha Gene Therapies, Inc.'s enterprise value increased by 367.9% year-over-year, from $229.99M to $1.08B.

What is the long-term trend for Taysha Gene Therapies, Inc.'s enterprise value?

Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s enterprise value has grown at a 46.2% compound annual growth rate (CAGR), from $275.38M to $1.26B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.